Clinical Study | Office of Clinical Research

Swog S1806 Phase III Randomized Trial Of Concurrent Chemoradiotherapy With Or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer

Posted Date: May 22, 2020

Investigator: Robert Franklin
Specialties: Cancer, Oncology
Type of Study: Drug

The primary goal of this study is to compare bladder intact event-free survival (BI-EFS) for concurrent chemoradiation therapy (CRT) with and without atezolizumab in localized muscle invasive bladder cancer (MIBC)

Criteria:

To Be Eligible: Must Have Urothelial Carcinoma Of The Bladder, Undergo Radiological Staging Within 70 Days, Zubrod Performance Status = 2, No Prior Malignancy Except Non-Melanoma Skin Cancer, No Systemic Chemotherapy For Bladder Cancer, No Major Surgery W

Keywords:

Bladder Cancer, Chemoradiotherapy

For More Information:

Uc Cancer Center
513-584-7698
cancer@uchealth.com

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List